Search Results
Your search for The matches 34676 pages
Showing 4551 - 4600New Predictive Epidemiologic Model May Identify Individuals at High Risk for Endometrial Cancer
Investigators have developed a predictive model that may be used in research and eventually clinical settings to identify individuals at high risk of developing endometrial cancer who would benefit from screenings, according to a report published by Shi et al in the Journal of the National Cancer...
Pancreatic Cancer Rates May Be Rising Faster Among Younger Women Than Younger Men
Investigators have confirmed that rates of pancreatic cancer are rising overall, but they are rising faster among younger female patients—particularly among patients who identified as Black—than among male patients of the same age, according to a new study published by Abboud et al in...
Recent FDA Approvals for Patients With Breast Cancer
On this episode, we’re reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant.
Second-Line Bevacizumab Plus FOLFIRI for Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
In a French noncomparative phase II trial (PRODIGE 41-BEVANEC) reported in The Lancet Oncology, Walter et al found that the addition of bevacizumab to FOLFIRI (irinotecan, leucovorin, and fluorouracil) did not appear to improve overall survival in the second-line treatment of patients with advanced ...
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer Without Disease Progression on Taxane Treatment
In a European phase II trial (Swiss Group for Clinical Cancer Research [SAKK] 08/16) reported in the Journal of Clinical Oncology, Silke Gillessen, MD, and colleagues found that darolutamide maintenance improved progression-free survival vs placebo in patients with metastatic castration-resistant...
Sublobar vs Lobar Resection for Peripheral Stage IA NSCLC
As reported in The New England Journal of Medicine by Nasser Altorki, MD, and colleagues, the phase III CALGB/Alliance 140503 trial showed that in respect to disease-free survival, sublobar resection was noninferior to lobar resection for patients with peripheral stage IA non–small cell lung cancer ...
Lack of Resources May Be Associated With Increased Mortality Rates Among Pediatric Cancer Survivors
Investigators have found that socioeconomic deprivation, the presence of modifiable chronic health conditions, and frailty may all independently be associated with increased rates of late mortality among pediatric cancer survivors, according to a new study published by Ehrhardt et al in JAMA...
Dietary Intervention May Help Reduce Chronic Fatigue, Improve Quality of Life for Cancer Survivors
Researchers have discovered that dietary interventions may help reduce fatigue, improve diet quality, and lead to an overall better quality of life for cancer survivors, according to a new study published by Weinhold et al in Nutrition and Cancer. Background For many cancer survivors, the side...
Addition of Pembrolizumab to Chemotherapy in First-Line Treatment of Metastatic Squamous NSCLC: 5-Year Update of KEYNOTE-407
As reported in the Journal of Clinical Oncology by Silvia Novello, MD, PhD, and colleagues, the 5-year update of the phase III KEYNOTE-407 trial showed continued overall survival and progression-free survival benefit with the addition of pembrolizumab to chemotherapy in the first-line treatment of...
Focal vs Extended Irreversible Electroporation in Ablation of Localized Low- or Intermediate-Risk Prostate Cancer
In a study reported in JAMA Surgery, Zhang et al found that focal and extended irreversible electroporation (IRE) produced similar results in the ablation of low- or intermediate-risk prostate cancer. Study Details In the study, 106 patients from five European centers were randomly assigned between ...
Diagnosis, Treatment, and Outcomes of Breast Cancer in Patients From Sex and Gender Minority Groups
In a single-institution study reported in JAMA Oncology, Eckhert et al found that patients with breast cancer from sex and gender minority groups experienced delayed diagnosis and had a shorter time to cancer recurrence compared to cisgender heterosexual patients. Study Details In the...
FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
On February 9, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient (dMMR), recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or...
Continued Declines in Cancer Mortality and Reductions in Cervical Cancer Incidence, but Increases in Advanced Prostate Cancer and Persistent Racial Disparities
The American Cancer Society (ACS) has released its Cancer Statistics 2023 report, which showed that overall cancer mortality has dropped by 33% since 1991, averting an estimated 3.8 million cancer deaths, according to the report. Data in the report also showed that women between the ages of 20 and...
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy: Health-Related Quality-of-Life Outcomes From a Randomized Clinical Trial
Guest Editor’s Note: Chemotherapy-induced peripheral neuropathy is a common and potentially debilitating side effect of neurotoxic chemotherapy. It worsens the quality of life for many cancer survivors, with limited treatment options. In this installment of The ASCO Post’s Integrative Oncology...
The Beauty and the Beast of Cancer
The most humbling—and fortunate—experience I’ve had since I was diagnosed with osteosarcoma 13 years ago at the age of 43 was being treated in the pediatric wing of a major cancer center in New York City. It is pretty difficult to feel sorry for yourself when you are sitting next to a 14-year-old...
Raised in Africa, Surgeon Kristin Flowers, MD, Continues the Tradition of Service in a Rural Hospital in Alaska
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kristin Flowers, MD, a general surgeon at Tanana Valley Clinic at Fairbanks Memorial Hospital in rural Alaska. Dr. Flowers’ surgical areas of interest include treating...
Traveling the World at an Early Age Gave Perspective and Balance to Future Oncology Leader Derek Raghavan, MD, PhD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Founding President of the Levine Cancer Institute. Established in 2011, the Levine Cancer Institute is part of Atrium Health (formerly the...
MD Anderson’s Guillermina Lozano, PhD, Receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, PhD, Chair of Genetics at The University of Texas MD Anderson Cancer Center, Houston, has received the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association...
Common Immune-Related Adverse Events: Spotlight on Gastrointestinal and Hepatic Toxicities
At the inaugural MD Anderson Clinical Education Symposium on Immunotherapy Organ Toxicity Management (IOTOX), a panel of experts discussed common immune-related adverse events associated with immune checkpoint inhibitor therapy, including gastrointestinal (GI), hepatic, dermatologic, pulmonary, and ...
Terry Hyslop, PhD, Joins SKCC as Cancer Risk and Control Program Co-Leader and Center for Health Equity Director
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently welcomed transdisciplinary population health researcher Terry Hyslop, PhD, as Co-Leader of the Cancer Risk and Control Program. Dr. Hyslop is returning to SKCC from the Duke Cancer Institute, where she served as Professor of...
KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials
KRAS G12C–mutated colorectal cancer represents 3% to 4% of metastatic colorectal cancers. Like other KRAS-mutated metastatic colorectal cancers, this group of patients represents a patient population with an unmet need, with limited options beyond two lines of therapy. In contrast to other KRAS...
Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation
In a phase I/II trial (KRYSTAL-1) reported in The New England Journal of Medicine, Rona Yaeger, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients ...
New JCO Oncology Practice Special Series Highlights Current State of Team-Based Care, Innovations, and Future Direction
What is team-based cancer care, and how has it evolved over the past decade? A special series in ASCO’s JCO Oncology Practice highlights transformations in team-based delivery models within the cancer care system and their potential direction. A carefully curated series of 15 peer-reviewed articles ...
ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer
A new ASCO guideline is available on the use of immunotherapy and biomarker testing for patients with recurrent or metastatic head and neck squamous cell carcinoma. The guideline provides recommendations related to PD-L1 and tumor mutational burden (TMB) testing, selection of therapy in the...
ASCO Formalizes Free Membership for Physicians in Lower-Middle–Income Countries
The ASCO Board of Directors recently took further action to support members in lower-middle–income countries. In alignment with ASCO’s strategic goal of making a global impact, the Board elected to expand free membership for physicians from lower-middle–income countries, as defined by the World...
Mosunetuzumab-axgb for Relapsed or Refractory Follicular Lymphoma
On December 22, 2022, mosunetuzumab-axgb, a bispecific CD20-directed CD3 T-cell engager, was granted accelerated approval for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1 Supporting Efficacy Data Approval was based on findings in the...
Quick Takes on Important Cancer Research From ASH 2022
The high-energy vibe at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition reflected the welcomed presence of enthusiastic on-site attendees and the high quality of the research presented. The ASCO Post has already reported in detail on many of these presentations, and now...
New Leaders Named for the University of Arkansas for Medical Sciences
The University of Arkansas for Medical Sciences (UAMS) has named Michelle W. Krause, MD, MPH, Senior Vice Chancellor for UAMS Health and Chief Executive Officer for UAMS Medical Center, and Ahmed Abuabdou, MD, MBA, Chief Clinical Officer for UAMS Medical Center. Dr. Krause and Dr. Abuabdou have...
Expert Point of View: Julio C. Chavez, MD
Julio C. Chavez, MD, Associate Member in the Lymphoma Section of the Department of Malignant Hematology at Moffitt Cancer Center, Tampa, who co-moderated the session where the glofitamab study was presented, shared his thoughts with The ASCO Post. “Glofitamab has great activity in high-risk...
Complete Response to Glofitamab at End of Treatment Heralds Prolonged Remission in Lymphoma
Patients with large B-cell lymphoma who achieve a complete response to glofitamab are very likely to remain in remission 12 months after the end of treatment, according to Martin Hutchings, MD, PhD, of Rigshospitalet in Copenhagen, who reported these findings at the 2022 American Society of...
Expert Point of View: Maryam B. Lustberg, MD, MPH
Maryam B. Lustberg, MD, MPH, Chief of Breast Medical Oncology at Yale Cancer Center, New Haven, shared her thoughts on TROPiCS-02 with The ASCO Post. “The progression-free survival and overall survival results of the phase III TROPiCS-02 trial position sacituzumab govitecan-hziy as an important...
Is Efficacy of Sacituzumab Govitecan-hziy in the TROPiCS-02 Trial Dependent on Trop-2 Expression?
The latest analysis of the TROPiCS-02 breast cancer trial showed that the antibody-drug conjugate sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio Breast Cancer Symposium by Hope S. Rugo, MD, FASCO, ...
Expert Point of View: Virginia Kaklamani, MD, Lori J. Pierce, MD, FASTRO, FASCO, and Eric Winer, MD, FASCO
Press briefing moderator Virginia Kaklamani, MD, Professor of Medicine at UT Health San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, said the findings from RxPONDER and those regarding the tumor microenvironment of metastasis (TMEM) doorway are ...
Despite Similar Recurrence Scores, Breast Cancer Outcomes Differ by Race
Suboptimal treatment, which often underlies worse outcomes for cancer in racial minorities, did not explain a recent finding from the landmark RxPONDER study: non-Hispanic Black women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer had worse outcomes compared with...
Expert Point of View: Polly Niravath, MD and Virginia Kaklamani, MD
The invited discussant of the SOFT analysis was Polly Niravath, MD, Associate Professor and Director of the Cancer Survivorship Program at Houston Methodist Hospital in Texas. She noted that the study evaluated the use of the Breast Cancer Index (BCI) as a prognostic tool in early hormone...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
Influence of the ‘Mark Cuban Effect’ on Cancer Drug Prices in the United States: Focus on CML
The advent of the BCR::ABL1 tyrosine kinase inhibitors for the treatment of Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) was a therapeutic miracle that changed the management paradigm of CML. The first of them, imatinib, was developed in the late 1990s.1,2 Within a few...
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
CAR T-Cell Therapy vs Chemoimmunotherapy in Second-Line Treatment of Resistant Large B-Cell Lymphoma
New research has confirmed the superiority of lisocabtagene maraleucel over the standard of care for the second-line treatment of primary refractory or early relapsed large B-cell lymphoma, according to data presented by lead study author Jeremy S. Abramson, MD, Associate Professor of Medicine at...
Docetaxel as a Radiosensitizer in Cisplatin-Ineligible Patients With Locally Advanced Head and Neck Cancer
In an Indian single-center phase II/III trial reported in the Journal of Clinical Oncology, Patil et al found that the use of docetaxel as a radiosensitizer was associated with better outcomes than radiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma who were...
Expert Point of View: David Wang, MD, PhD
“We can say with confidence that based on the results of the SPOTLIGHT trial,1 zolbetuximab is the first molecularly targeted therapy since [trastuzumab in] the TOGA trial,2 exclusive of immune checkpoint inhibitors, to demonstrate a statistically significant survival benefit in the first-line...
Subset of Patients With Advanced Gastric Cancer May Benefit From Claudin18.2-Targeted Agent Zolbetuximab
Initial data from the global phase III SPOTLIGHT trial may herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction adenocarcinoma.1 The addition ofzolbetuximab, which targets the transmembrane protein claudin18.2 (CLDN18.2), to chemotherapy ...
Proton Therapy Reirradiation in Recurrent Head and Neck Squamous Cell Carcinoma
In a single-institution retrospective cohort study reported in JAMA Network Open, Lee et al found that proton therapy reirradiation (PT-ReRT) may be associated with improved survival in patients with recurrent head and neck squamous cell carcinoma, with a fractionated regimen being associated with...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology and Association for Clinical Oncology, issued the following statement after President Joseph R. Biden’s State of the Union address earlier this week. “ASCO applauds...
Findings on Cardiovascular Imaging in Patients Receiving Ibrutinib: Association With Cardiotoxicity
In a study reported in JAMA Oncology, Buck et al found that myocardial injury detected on cardiovascular magnetic resonance imaging (CMR) was common in patients treated with ibrutinib and was associated with an increased risk of major adverse cardiac events. Study Details The study included data...
New Study Highlights Impact of COVID-19 Pandemic on Cancer Screening Delays
Investigators have found further evidence to quantify the vast, lingering impact of the global COVID-19 pandemic on timely cancer screening—highlighting the urgent need for health-care providers to address significant delays to cancer screenings in populations most likely to delay testing,...
Half of Patients With Cancer May Develop Long COVID, With Risk Higher in Female Patients
More than one in two patients with cancer may experience symptoms of long COVID for more than 6 months after initial COVID-19 infection, according to a new study published by Dagher et al in eLife. The findings were comparable to the reported incidence of long COVID in the general population, but...
Higher Rate of Clonal Hematopoiesis in Pediatric Cancer Survivors May Be Linked With Treatment-Induced STAT3 Gene Mutations and Risk of Adverse Long-Term Outcomes
Studies show that although clonal hematopoiesis is an age-related phenomenon in the general population, it can also be induced by exposure to chemotherapy, which can affect both the emergence and evolution of clonal hematopoiesis clones, accelerating aging at both the physiologic and molecular...
Long-Term Outcomes Among Survivors of Wilms Tumor
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in the Journal of Clinical Oncology, Weil et al found that survivors of unilateral Wilms tumor were at an increased risk for severe chronic health conditions. Study Details The study involved 2,008 5-year survivors diagnosed...
Carl H. June, MD, Honored With 2023 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) will award Carl H. June, MD, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting 2023, taking place from April 14 to 19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in...
